Acute Pancreatitis
Conditions
Interventions
Vit C group:continuos intravenous injection of Vitamin C with 200 mg/kg/h for 7 days
NS group:continuos intravenous injection of normal saline using the same dose as Vit C for 7days
Sponsors
Department of emergency, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years; 2. Onset within 72 hours; 3. Meeting the diagnostic criteria for acute pancreatitis(meeting 2 of the following 3 features); (1) Abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back); (2) Serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal; (3) Characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CECT) and magnetic resonance imaging (MRI). 4. Meeting the grades of severity for moderately severe/severe acute pancreatitis (1) Moderately severe acute pancreatitis: Organ failure that resolves within 48 h (transient organ failure) and/or local or systemic complications without persistent organ failure A.Definition of organ failure and systemic cmplications: Respiratory: PaO2/FiO2=300; Cardiovascular: systolic blood pressure=90 mm Hg (off inotropic support), not fluid responsive or PH48 h) 5. Sign the consent.
Exclusion criteria
Exclusion criteria: 1. In the period of pregnant or lactation; 2. Pancreatits resulting from malignant tumor or ERCP; 3. Be allergic to Vitamin C; 4. With severe chronic dysfunction of heart, liver, lung, renal or blood system before admission; 5. With kidney stone; 6. Uncured malignant tumor; 7. With autoimmune disease or immunosuppressive state (having accepted solid organs or bone marrow transplantation, AIDS, long-term use of immunosuppressive agents or hormones, etc.); 8. With some special device (eg. pacemaker); 9. Involved in other clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28 days mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| indication for organ function(liver,kidney,heart,lung,coagulation);sequential organ failure assessment (SOFA) score,acute physiology and chronic health evaluation II ( APACHEII ) score;VitC related adverse event(urine crystal,urine volume per day,indicatiors for kidney function);period for ventilation;period for renal replacement therapy;period for vasoactive agents application;time and procedure of surgical intervention;90 days mortality;ROS, RNS, 8-OHdG, MDA, GSH;TNF-a, IL-6, IL-10;plasma level of VitaminC; | — |
Countries
China
Contacts
Public ContactChen Ying
Department of emergency, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed